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Background: The prognostic value of lymphovascular invasion (LVI) in breast cancer (BC) has been demonstrated in several
independent studies. However, identification of driver molecules for LVI remains a challenging task. Large-scale transcriptomic
profiling of histologically validated LVI can potentially identify genes that regulate LVI.
Methods: Integrative bio-informatics analyses of the METABRIC study were performed utilising a subset of strictly defined LVI
using histological and immunohistochemical (IHC) criteria. ARHGAP18 was among the top differentially expressed genes between
LVIþ and LVI BC with a 1.8-fold change. The prognostic impact of ARHGAP18 gene expression was assessed in the METABRIC
data set (n¼ 1980) and externally validated using the online BC gene expression data sets utilising bc-GenExMiner v4.0 (n¼ 2016).
Subsequently, ARHGAP18 protein expression was assessed on a large cohort of invasive BC (n¼ 959) with long-term follow-up
using IHC.
Results: Pooled analysis of ARHGAP18 mRNA expression showed that overexpression was associated with better outcome
(Po0.001, hazard ratio (HR)¼ 0.82, 95% CI 0.75–0.90). ARHGAP18 protein was expressed in the cytoplasm and nuclei of the tumour
cells and its expression was positively associated with good prognostic variables. Lack of cytoplasmic expression showed
associations with LVI (P¼ 0.006), epithelial-mesenchymal transition and the HERþ subtype (P¼ 0.01). Loss of nuclear expression
was associated with higher grade, HER2þ and high Ki67LI (P¼ 0.001). Cytoplasmic and nuclear expression showed a positive
association with improved survival independent of other variables (P¼ 0.01, HR¼ 0.74, 95% CI 0.60–87).
Conclusions: ARHGAP18 expression at transcriptomic and protein levels is associated with improved patients’ outcomes whose
deregulation may play a role in tumour progression and the development of LVI in BC. Further assessment of its potential
therapeutic value in BC is warranted.
Lymphovascular invasion (LVI) is an indicator of metastatic
potential and poor outcome in breast cancer (BC) (Lee et al, 1990;
Quinlan, 1993; Altman and Bland, 1994; Lauria et al, 1995; Choi
et al, 2003; Truong et al, 2005; Debled et al, 2010; Song et al, 2011;
Ugras et al, 2014). In a previous study (Quinlan, 1993) we have
demonstrated that in a lymph node-negative BC cohort, LVI could
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be used as a high-risk criterion conferring survival disadvantage
equivalent to that provided by involvement of one or two lymph
nodes and to that provided by one higher size category (pT1 to
pT2) (Quinlan, 1993). Despite its recognised prognostic roles, the
molecular mechanisms underlying the development of LVI in BC
and genes driving this process that could be used as potential
therapeutic targets remain largely unknown (reviewed in
Aleskandarany et al, 2015). This is related not only to the
complexity of the mechanisms involved in the development of LVI
as part of the invasion-metastasis process and the complex
interaction between tumour cells and their microenvironment
but also due to the difficulty in studies’ design and the subjectivity
of identification of true LVI-negative and LVI-positive BC. Here
we hypothesised that large-scale transcriptomic and genomic
profiling of a cohort with strictly defined LVI status could
potentially yield candidate key/driver genes. This approach is likely
to narrow down the number of potential genes that can be further
investigated using in vitro and in vivo assays models with the aim
of identifying novel therapeutic targets.
In this study, the Molecular Taxonomy of Breast Cancer
International Consortium (METABRIC) data were used for
exploring genes associated with LVI in invasive BC through
extensive genome-wide analysis of gene expression and copy
number aberrations (CNAs) (Curtis et al, 2012). LVI was defined
using strict criteria with the aid of immunohistochemistry (IHC).
Genes with significant differential expression were ranked accord-
ing to the strength of their association with LVI. The CNAs of
these genes were determined. One of the top genes that is currently
gaining interest as a therapeutic target (Rao et al, 2015a) showed
differential expression together with CNAs was the Rho-GTPase
activating-protein 18 (ARHGAP18). The prognostic impact of
ARHGAP18 gene expression was externally validated using online
BC gene expression data sets. Protein expression of ARHGAP18
was assessed on a large clinically annotated cohort of invasive BC
with long-term follow-up using IHC. The association between
ARHGAP18 and LVI as well as clinicopathologic criteria and
patients’ outcome were explored.
MATERIALS AND METHODS
Gene identification using METABRIC cohort. To identify
putative LVI driver genes, the METABRIC cohort data were
explored as regards the gene expression and CNA between cases
with definite LVI and cases with no evidence of LVI. Details of
tissue processing, analysis and interpretation of the findings of the
METABRIC study were previously described (Curtis et al, 2012).
Briefly, the extracted and purified DNA probes were hybridised to
Affymetrix SNP 6.0 arrays (Affymetrix, Santa Clara, CA, USA) at
AROS Applied Biotechnology (Aarhus, Denmark). The Illumina
Totalprep RNA amplification kit (Ambion, Warrington, UK) was
used, and then hybridised onto Illumina Human HT-12 v3
Expression Beadchips from the same manufacturer. For this
purpose, the discovery set formed of cases from Nottingham
primary series of invasive BC included in the METABRIC study
(n¼ 328). Tumours in this discovery set were treated using
standardised methods of specimen fixation, sampling and proces-
sing as previously described (Rakha et al, 2012). The clinicopatho-
logical data including LVI status, axillary nodal status and other
variables were available. The LVI status of these cases was
determined using a set of criteria as follows: cases were defined
as LVI positive (LVIþ ) when LVI was reported in routine practice
as positive based on H&E sections of the whole tumours and LVI
was confirmed using IHC using CD34 and/or D2–40 (Rakha et al,
2012) on one full-face tumour section from the surgical specimens.
LVI-negative (LVI ) cases were defined by negativity of LVI on
both H&E sections and IHC. Importantly, cases in the discovery
set with positive lymph nodes in the LVI subgroup were
excluded to avoid bias caused by potentially undetectable foci of
LVI in the primary tumour. This discovery set was used to identify
genes differentially expressed between the two LVI subgroups that
are likely to be related to LVI. The validation set (Addenbrookes
cases; n¼ 914 cases) set was used to validate the expression of the
differentially expressed genes, to ensure that genes were differen-
tially expressed in both the Nottingham and Addenbrookes
cohorts. To test for genes/transcripts significantly differentially
expressed between LVIþ and LVI cases, a supervised
differential gene expression analysis approach of gene expression
data was followed. This was performed using the Linear Model for
Microarray and RNA-seq data (LIMMA) software package that is
compatible with the Affymetrix data. The Affymetrix SNP 6.0 array
data were further analysed for CNAs of each transcript in the list of
top associated genes with LVI using Affymetrix SNP6 Copy
Number Inference Pipeline (Cancer Genomics Computation
Analysis group of the Broad Institute, USA). The top differentially
expressed genes were ranked based on their P-value of association
with LVI. Subsequently the CNAs of the top differentially
expressed genes were determined. Of the top five differentially
expressed genes, ARHGAP18 was identified.
ARHGAP18 gene expression. ARHGAP18 gene expression was
evaluated in the METABRIC cohort of 1980 BC samples (Curtis
et al, 2012). In this cohort, patients with ER-positive and/or lymph
node-negative tumours did not receive adjuvant chemotherapy,
while those with ER-negative and/or lymph node-positive tumours
received adjuvant chemotherapy. Dichotomisation of ARHGAP18
mRNA expression was performed at the median mRNA expression
of the studied cohort.
External validation. To further assess the prognostic significance
of ARHGAP18 mRNA expression, bc-GenExMiner v4.0 (Breast
Cancer Gene-Expression Miner v3.0) online data set (http://
bcgenex.centregauducheau.fr) was used. This is composed of two
statistical mining modules; the ‘prognostic module’, offering the
possibility to evaluate the in vivo prognostic impact of candidate
genes in BC, and the ‘correlation module’, to compute correlation
coefficients between gene expressions or to find lists of correlated
genes in BC. The prognostic module was in this external validation,
where Cox model, Kaplan–Meier and forest plots were performed
(Jezequel et al, 2012). The prognostic significance was used as LVI
status was not available for these cohorts.
ARHGAP18 protein expression. ARHGAP18 protein expression
was assessed in formalin-fixed paraffin-embedded tissue samples
from BC cases enrolled into the Nottingham Tenovus Breast
Carcinoma Series: a well-characterised series of primary operable
invasive BC presenting between 1987 and 1998 at Nottingham City
Hospital (n¼ 959). Clinical and pathological data had been
recorded and patients’ outcome data are regularly updated and
prospectively maintained. Outcome data recorded included
survival status, mean survival in months, recurrence of disease
(including distant metastases) and cause of death. Disease-free
interval (DFI) was defined as months from date of primary surgery
to appearance of local, regional, or distant recurrence, breast
cancer-specific survival (BCSS) was defined as months from
primary surgery until BC-specific death, and time to distant
metastasis (distant metastasis-free interval, DMFI) was defined as
months from primary surgery to occurrence of first distant
metastasis/recurrence. Adjuvant therapy was based upon tumour
prognostic and predictive factors including the Nottingham
Prognostic Index (NPI), lymph node (LN) status, menopausal
status and ER positivity/negativity and included hormonal therapy
and CMF (cyclophosphamide, methotrexate and 5-Flourouracil).
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Expression of a large number of molecular biomarkers relevant
to BC tumourigenesis and progression including oestrogen
receptor (ER), progesterone receptors (PR), human epidermal
growth factor receptor 2 (HER2), p53, Ki67, and others have been
previously studied (Abd El-Rehim et al, 2005). The tumours were
subtyped into luminal (ERþ /PRþ /HER2 ), HER2þ , and triple
negative (PR /ER /HER2 ) subtypes (Rakha et al, 2009).
Table 1 summarises the clinicopathological data of this cohort. The
median and mean age of the study population was 54 years (range:
24–70). The median overall survival in months was 168 months
while the median DFI was 109 months. This work was approved by
Nottingham Research Ethics Committee 2 under the title:
Development of a molecular genetic classification of breast cancer.
All tissue samples included in this study were from patients who
were consented prior to inclusion in the study cohort.
Validation of primary antibody specificity using western blotting.
Prior to IHC, the specificity of the anti-ARHGAP18 antibody
(ab175970, Abcam, UK) was validated using western blotting
performed on whole cell lysates of high expressor cells of
ARHGAP18 mRNA according to the manufacturer’s protocol.
For this purpose, lysates of human cervical cancer (HeLa CCL-2,
American Type Culture Collection (ATCC), USA) cell lines and
human breast adenocarcinoma (MDA-MB-231, ATTC HTB-26,
USA) cell lines were used. This was performed using 1 : 1000
dilution of the primary antibody (ab175970, Abcam, UK), and
1 : 15 000 of the horseradish peroxidase-labelled secondary anti-
rabbit antibody, with b-actin (diluted 1 : 2000) used as a loading
control. Bovine serum albumin was used for blocking. Enhanced
chemiluminescence was used to visualise the membrane as
previously described (Mruk and Cheng, 2011). The images were
developed via chemiluminescence using an Odyssey Fc (Li-cor
Bisosciences, Lincoln, NE, USA).
Immunohistochemistry. Heat-assisted antigen retrieval was per-
formed in accordance to the manufacturer’s recommendations
(citrate buffer pH 6.0 at 1000W for 20min using microwave). The
Novolink Max Polymer Detection System was used to visualise the
reaction (RE7280-k, Leica, Newcastle, UK). Endogenous perox-
idase activity was blocked by the addition of a peroxidase block
(Novolink Peroxidase Block) for 5min. Non-specific binding of the
primary antibody, post primary block (Novolink Protein block)
was used. The slides were washed and incubated with the anti-
ARHGAP18 primary antibody (ab175970, Abcam, UK, diluted
1 : 75 in Bond Primary Antibody Dilutent, Leica, Germany), for
30min at room temperature. This working dilution was chosen
based on repeated attempts of optimisation using different
dilutions, guided by the manufacturer’s recommendation, in order
to achieve specific staining with minimal background. The positive
control, b2 microglobulin (Polyclonal Rabbit Anti-Human Beta-2-
Microglobulin, Dako, Glostrup, Denmark) was incubated at
1 : 2000 dilution. A DAB (3,30-diaminobenzadine) in a buffered
stabiliser solution (Novolink DAB Chromogen; 1 : 20 dilution) was
added to the slides for 5min. The slides were counterstained with
haematoxylin for 6min (Novolink Haematoxylin). Dehydration,
clearing, mounting and cover-slipping were performed as pre-
viously described. Full-face tissue sections from 25 BC excision
specimens were also stained for ARHGAP18 to assess for the
distribution of staining to decide for TMAs suitability. Negative
and positive controls (by omission of the primary antibody, and
human liver tissues, respectively) were included in each staining
run.
Scoring of TMA cores. Stained TMA slides were digitally scanned
(NanoZoomer, Hamamatsu Photonics, Tokyo, Japan) to high
resolution images and viewed by Aperio ImageScope (Aperio
Technologies, Milton Keynes, UK) at  20 magnification. Cores/
Table 1. Summary of patient demographics of the
Nottingham primary BC series used in this study
Parameter Number (%)
Age
p50 years 367 (38.3)
450 years 591 (61.6)
Median/mean 54
Menopausal status
Premenopausal 381 (39.7)
Postmenopausal 577 (60.2)
Tumour grade
1 129 (13.6)
2 300 (31.6)
3 521 (54.8)
Pleomorphisms
1 13 (1.4)
2 314 (33.9)
3 599 (64.7)
Tubule formation
1 45 (4.8)
2 308 (33.3)
3 574 (61.9)
Mitotic figures
1 267 (28.8)
2 196 (21.2)
3 463 (50.0)
Tumour size
p2 cm 543 (56.6)
42 cm 404 (42.1)
Axillary nodal stage
1 (Node negative) 571 (59.5)
2 (1–3 positive nodes) 304 (31.7)
3 (X4 positive nodes) 78 (8.1)
Nottingham Prognostic Index (NPI)
Good NPI (o3.4) 247 (26.0)
Moderate NPI (3.41–5.4) 530 (55.7)
Poor NPI (X5.4) 174 (18.3)
Histological tumour type
Ductal no special type (NST) 578 (62.3)
Tubular mixed 158 (17.0)
Medullary (typical and atypical) 23 (2.5)
Lobular* 73 (7.9)
Excellent Prognosis Special Groups** 38 (4.1)
Mixed NST and lobular 39 (4.2)
Mixed NST and other special type 19 (2.0)
LVI Negative 612 (65.2)
Definite 327 (34.8)
Distant metastasis
Negative 567 (60.1)
Positive 376 (39.2)
Survival (month)
Overall survival: Median/mean (range) 168/149.6 (1–308)
DFI: Median/mean (range) 109/100 (2–239)
ER status
ER positive 271 (28.5)
ER negative 681 (71.5)
PR status
PR positive 407 (43.8)
PR negative 522 (56.2)
HER2 status
HER2 positive 786 (85.4)
HER2 negative 131 (13.2)
Molecular subtype
Luminal 614 (65.9)
HER2 positive 131 (14.1)
Triple negative 187 (20.0)
Abbreviations: ER¼oestrogen receptor; HER2¼ human epidermal growth factor receptor
2; LVI¼ lymphovascular invasion; PR¼progesterone receptors.
*Invasive lobular includes: classic lobular, tubulo-lobular, alveolar lobular, solid lobular,
pleomorphic lobular, and lobular mixed carcinomas.
**Excellent prognostic special types comprise: mucinous carcinoma, cribriform carcinoma,
tubular carcinoma and invasive papillary carcinoma.
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images were individually evaluated and assigned an ‘H-Score’ by
identification of the percentage of the malignant cells that were
stained (0–100) and the staining intensity (0 – negative, 1 –weak, 2
– moderate and 3 – strong), and the final H-Score was calculated as
previously described (McCarty et al, 1985). Scoring was performed
by a single observer (RS) and a subset of cases (20%) was scored by
an independent observer (MA) to assess inter-rater reliability. All
identifying patient information and clinical variables were
completely anonymised during scoring.
Statistical analysis. The H-Scores were linked to anonymised
patient codes to match all other variables with biomarker
expression. Analysis was performed in the statistical software
package SPSS (IBM SPSS statistics, Version 22). The data were
exported to X-Tile (X-Tile Bioinformatics Software, Yale Uni-
versity, version 3.6.1) to determine an unbiased optimally
significant cut off point based on patients’ outcomes. Kappa
statistic was used to test scoring reproducibility between observers
(inter-observer agreement). Analyses were performed for nuclear
and cytoplasmic H scores independently. Univariate analysis was
performed using the chi-squared test to evaluate the significance of
the association between expression of the biomarkers and the
clinicopathological parameters of the data, as well as other
previously investigated biomarkers. Kaplan–Meier analysis was
performed to assess BCSS and DFI survival differences. Multi-
variate Cox Regression analysis with adjustment of co-variates was
fitted to test independence from standard prognostic factors. A
P-value of o0.05 (two tailed) was considered significant.
RESULTS
Gene identification using the METABRIC study. Analysis of the
METABRIC transcriptomic data in the discovery and validation
sets revealed 514 genes differentially expressed with regard to LVI
status. These genes were ranked in order based on the P-value of
expression. Biological functions of the top differentially expressed
genes were also assessed using published literature. In addition, the
CNAs of these genes were analysed to identify those genes whose
expression was associated with their gene CNAs (cis acting). Of the
top five genes that showed differential expression associated with
CNAs with regard to LVI was ARHGAP18 and this gene was
subject to further analysis in this study.
Using the median expression as a cut-off point, high
ARHGAP18 mRNA expression was significantly associated with
variables of good prognosis including smaller size (Po0.04), early
stage (Po0.001), tumours of tubular subtype (Po0.001) and
HER2 tumours (P¼ 0.029). When comparing the levels of
ARHGAP18 mRNA expression in the intrinsic (PAM50) subtypes,
significant differences were observed (P¼ 0.006), with the HER2þ
subtype showing the least expression levels. Similarly, significant
difference in the expression levels were observed within the
different METABRIC Integrative Clusters (P¼ 0.021), with clusters
5 (ERBB2 amplified) and cluster 9 (Luminal B subgroup) showed
the least ARHGAP18 mRNA expression. A trend towards
significantly improved patients’ survival (P¼ 0.082) in ARHGAP18
mRNA over-expression was also identified.
ARHGAP18 mRNA expression levels in the external validation
cohorts. The prognostic impact of ARHGAP18 mRNA expression
was subsequently assessed using bc-GenExMiner v4. (Breast
Cancer Gene-Expression Miner v4) online data set as external
validation cohorts (n¼ 21 data sets, 4177 patients). Of these, 12
data sets provided information on DMFI for ARHGAP18 mRNA
expression. As shown in the Forest plot (Supplementary Figure 1),
4 out of 12 studies showed high ARHGAP18 mRNA expression
was significantly associated with improved DMFI; however, the
remaining eight studies did not show significant associations.
When the data were pooled together (n¼ 2016), high ARHGAP18
mRNA expression was significantly associated with longer DMFI
(Po0.001, hazard ratio (HR)¼ 0.82, 95%CI 0.75–0.90),
Supplementary Figure 2. Interestingly, exhaustive prognostic
analysis, which permits to screen the prognostic impact of
ARHGAP18 mRNA on all possible combinations of population,
showed significantly improved outcome of patients in 9 out of 18
studies using all possible combinations, Supplementary Table 1.
Immunohistochemical expression of ARHGAP18. Validation of
the antibody specificity using western blot showed a single specific
band at the predicted size (75 kDa) of ARHGAP18 protein,
confirming the specificity of the antibody, Figure 1A. Full-face
sections stained with ARHGAP18 antibody showed homogenous
staining distribution throughout stained sections; therefore,
validating the use of TMA. IHC expression showed ARHGAP18
protein was localised in the nuclei and cytoplasm of tumour cells
with varying intensities, Figure 1B–D. In addition, positivity was
observed in the cells of ductal carcinoma in situ and in the normal
ductal epithelial cells entrapped in some cores. Overall, the
expression was reduced in some invasive tumours compared to
the cells of the in situ component or the normal ductal cells.
Cases re-scored by an independent observer showed a very good
(Kappa¼ 0.83) agreement between the two scorers. The H-Scores
of both nuclear and cytoplasmic expression did not follow normal
distribution. X-Tile determined optimal cut-off values as H-Score
140 for cytoplasmic staining, and 65 for nuclear staining. At these
cut-offs, 848 out of 959 (88.4%) cases showed negative/low nuclear
expression and 111 out of 959 (12.6%) showed positive/high
nuclear expression. Cases with cytoplasmic staining were dichot-
omised as 784 out of 959 (81.8%) cores negative/low expression
and 175 out of 959 (18.2%) with positive/high expression.
ARHGAP18 protein expression and clinicopathological vari-
ables. Cytoplasmic expression of ARHGAP18 showed an inverse
association with the LVI (P¼ 0.006) and Nottingham Prognostic
Index (NPI, P¼ 0.010; Table 2). Loss of its expression was
associated with epithelial mesenchymal transition with loss of
E-cadherin and overexpression of N-cadherin, and with HER2
overexpression. Consistent with mRNA expression, ARHGAP18
cytoplasmic protein expression showed an association with IHC-
defined molecular subtypes where it was less expressed in the
HER2þ and TNBC classes (P¼ 0.035; Table 3). Nuclear
expression of ARHGAP18 was associated with lower grade
(P¼ 0.022), with less mitotic counts and nuclear pleomorphism,
smaller tumour size (P¼ 0.002), the better prognostic NPI
subgroup (P¼ 0.001), histological types of excellent/good prog-
nosis (P¼ 0.002) but not with LVI (Table 4). Positive nuclear
expression showed significant associations with HER2 negativity
(P¼ 0.003), negative/low Ki67 (P¼ 0.001) luminal-A subtype
(P¼ 0.001), and the negative/low expression of N-cadherin,
transforming growth factor b (TGF-b1), PIK3CA and C-terminal
tensin-like (CTEN) (Po0.05; Table 5).
Similar statistical associations were observed when the expres-
sion of ARHGAP18 was taken into account irrespective of the
localisation (i.e. negative versus positive cytoplasmic or nuclear
expression).
Expression of ARHGAP18 patient outcome. Increased cytoplas-
mic expression of ARHGAP18 was significantly associated with
improved outcome in terms of longer BCSS (P¼ 0.004) and DMFI
(P¼ 0.012; Figure 2). Using multivariate cox regression analysis,
this association was independent of tumour size, tumour grade,
nodal stage and BC molecular subtype (P¼ 0.017, HR¼ 0.68, 95%
CI 0.49–0.93, and P¼ 0.031, HR¼ 0.72, 95% CI¼ 0.54–0.97, for
BCSS and DMFI, respectively). High nuclear expression was also
significantly associated with longer BCSS (P¼ 0.001) and DMFI
(P¼ 0.003; Figure 3). Again, similar statistical associations with
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patients’ outcome were observed when the expression of
ARHGAP18 was taken into account irrespective of the localisation.
These associations were independent of the standard prognostic
factors including tumour size, nodal stage and tumour grade using
Cox proportional multivariate analysis (P¼ 0.023, HR¼ 0.62, 95%
CI¼ 0.41–0.94, and P¼ 0.047, HR¼ 0.69, 95% CI¼ 0.47–0.10, for
BCSS and DMFI, respectively).
DISCUSSION
The ARHGAP genes encode a family of at least 32 members of
RhoGAP proteins with variable functions (Katoh and Katoh,
2004). The downstream target of the ARHGAPs is the Rho GTPase
protein family; therefore, they are logical candidates to investigate
their roles in BC. Members of the Rho GTPase family have
numerous cellular functions including maintenance and control of
the actin cytoskeleton, angiogenesis, cell proliferation, differentia-
tion, and survival (Peck et al, 2002). Consequently, deregulation of
these proteins has been implicated in multiple types of tumours. In
this study and using an integrative bio-informatics analysis of gene
expression and CNA data associated with LVI coupled with strict
defining criteria for definition of LVI in BC we have identified
ARHGAP18 as one of the top differentially expressed genes and its
expression was associated with its gene CNA. ARHGAP18 is
located on chromosome 6q22.33 and is a member of the ARHGAP
family (Potkin et al, 2008). After confirmation of its prognostic
value in the METABRIC cohort and in external validation series,
we sought to assess the protein expression of ARHGAP18 in a large
unselected annotated series of BC with long-term follow-up.
Studies exploring the impact of tissue-based ARHGAP18
protein expression in cancers including BC are lacking and most
of the studies so far were performed using in vitro tissue culture
platform. In the current study, ARHGAP18 IHC staining was
detected in the cytoplasm and in the nuclei of invasive BC cells
with variable percent and intensity, in the cells of ductal carcinoma
in situ and in the normal ductal epithelial cells. An overall
tendency of reduced expression was observed in invasive tumours
compared to the non-invasive and normal ductal cells, with the
latter showing the highest expression; observations which may be
denoting a tumour suppressor role.
Cytoplasmic expression of ARHGAP18 showed significant
negative association with LVI. Recently, Chang et al reported on
roles of ARHGAP18 in limiting proangiogenic signalling and
promoting vascular stability through limiting endothelial cell
kDa
A B
DC
250
1 2 3 4
130
100
70
55
35
25
15
10
ARHGAP18 β-Actin
Figure 1. Western blot and immunohistochemical expression of ARHGAP18 in BC. (A) Western blot of ARHGAP18 and the housekeeping Beta-
actin. Western blotting performed on whole cell lysates of HeLa CCL-2 and MDA-MB-231 (lanes 1 and 2, respectively). Primary antibody (Anti-
ARHGAP18, 1 : 1000 dilution), and of the HRP-labelled secondary anti-rabbit antibody (1 : 15 000), with b-actin (1 : 2000, lanes 3 and 4) used as a
loading control. The images were developed via chemiluminescence using an Odyssesy Fc (Li-cor Bisosciences, USA). (B–D) Immunohistochemical
expression of ARHGAP18 in invasive BC: (B) Negative, (C) Invasive BC case showing positive cytoplasmic expression, and (D) a case of invasive BC
case showing both nuclear and cytoplasmic expression.
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sprouting and stabilising junctional integrity (Rao et al, 2015b).
Moreover, knockdown of ARHGAP18 has been recently reported
to promote endothelial cells migration in scratch wound assay with
a protrusive and irregular migratory front and disrupted cell
junctions at the proximal edge of the leading cell (Chang et al,
2014). Sustained angiogenesis is one of the hallmarks of cancer and
is essential for tumour progression. Moreover, in the current study,
reduced expression was associated with high Ki67, epithelial
mesenchymal transition with expression of N-cadherin and TGFb1
and reduced expression of E-cadherin. Similar significance was also
identified with nuclear expression, showing positive association
with other prognostic variables and outcome. A large proportion of
cases strongly expressing ARHGAP18 were of the excellent
prognosis histological subtypes including tubular, invasive cribri-
form and mucinous carcinomas. Nuclear expression was also
significantly associated with lower tumour grade, lower mitotic
scores, less nuclear pleomorphism and smaller tumour size. Such
associations suggest ARHGAP18 may be a marker of related to
tumour differentiation.
Investigations specifically pertaining to the subcellular localisa-
tion of ARHGAP18 are lacking. However, similar to findings of the
current study with ARHGAP18 in BC it has been reported that
ARHGAP21 is localised both in the cytoplasm and nuclei of
prostatic carcinoma (Barcellos et al, 2013) and nuclear and
perinuclear localisation seen in glioblastoma-derived cell lines
(Bigarella et al, 2009). We suggest ARHGAP18 might have a
similar trafficking from the cytoplasm, where synthesis occurs, to
the nucleus, possibly upon occasion of tumourigenic changes.
Table 2. Statistical association of cytoplasmic H score
expression of ARHGAP18 and the clinicopathological
parameters of the studied series
ARHGAP18 cytoplasmic
expression
Parameter
Low no.
(%)
High no.
(%) v2 P-value
Patients’ age
p50 yrs 290 (79.0) 77 (21.0) 3.178 0.075
450 yrs 494 (83.6) 97 (16.4)
Menopausal status
Premenopausal 303 (79.5) 78 (20.5) 2.270 0.132
Postmenopausal 481 (83.4) 96 (916.6)
Grade
1 98 (76.0) 31 (24.0) 3.439 0.179
2 247 (82.3) 53 (17.7)
3 432 (82.9) 89 (17.1)
Mitotic figures
1 221 (82.5) 47 (17.5)
2 154 (78.6) 42 (21.4) 1.713 0.425
3 383 (82.7) 80 (17.3)
Pleomorphisms
1 8 (61.5) 5 (38.5)
2 249 (79.3) 65 (20.7) 6.015 0.049
3 500 (83.5) 99 (16.5)
Tubule formation
1 34 (75.6) 11 (24.4)
2 242 (78.6) 66 (21.4) 5.147 0.075
3 482 (84.0) 92 (16.0)
Axillary nodal stage
1 458 (80.2) 113 (19.8)
2 258 (84.9) 46 (15.1) 2.900 0.235
3 64 (82.1) 14 (17.9)
Tumour size
p2 cm 437 (80.5) 106 (19.5) 1.581 0.209
42 cm 338 (83.7) 66 (16.3)
NPI
Good (o3.4) 195 (78.9) 52 (21.2)
Moderate (3.41–5.4) 431 (81.3) 99 (18.7) 17.898 0.010
Poor (X5.41) 152 (87.4) 22 (12.6)
Vascular invasion
Negative 485 (79.2) 127 (20.8) 7.617 0.006
Definite 283 (86.5) 44 (13.5)
Tumour type
Ductal carcinoma No
Special Type (NST)
476 (82.4) 102 (17.6)
Tubular mixed 125(79.1) 33(20.9)
Medullary-like 21(91.3) 2 (8.7) 7.914 0.244
Invasive lobular 63 (86.3) 10 (13.7)
Excellent Prognosis
Special Type**
26 (68.4) 12 (31.6)
Mixed NST and lobular 32 (82.1) 7 (17.9)
Mixed NST and other
special type
16 (84.2) 169 (18.2)
Abbreviation: NPI¼Nottingham Prognostic Index.
**Excellent prognostic special types comprise: mucinous carcinoma, cribriform carcinoma,
tubular carcinoma and invasive papillary carcinoma.
Table 3. Statistical association of cytoplasmic H score
expression of ARHGAP18 and the expression of other
biomarkers
ARHGAP18 cytoplasmic
expression Significance
Parameter Low no. (%) High no. (%) v2 P-value
ER
Negative 227 (83.8) 44 (16.2) 0.955 0.328
Positive 552 (81.1) 129 (18.9)
PR
Negative 343 (84.3) 64 (15.7) 2.962 0.085
Positive 417 (79.9) 105 (20.1)
HER2
Negative 636 (80.9) 150 (19.1) 5.391 0.019
Positive 117 (89.3) 14 (10.7)
Molecular subtypes
Luminal 492 (80.1) 122 (19.9)
HER2þ 117 (89.3) 14 (10.7) 6.719 0.035
Triple negative 157 (84.0) 30 (16.0)
p53
Negative 528 (82.2) 114 (17.8) 0.081 0.776
Positive 224 (81.5) 51 (18.5)
Ki67
Negative 179 (82.1) 39 (17.9) 0.004 0.951
Positive 435 (81.9) 96 (18.1)
E-Cadherin
Negative 284 (86.1) 46 (13.9) 5.223 0.023
Positive 448 (80.0) 112 (20.0)
N-Cadherin
Negative 147 (78.6) 40 (21.4) 5.752 0.019
Positive 440(86.1) 71 (13.9)
TGF-b1
Negative 274 (79.7) 70 (20.3) 1.465 0.262
Positive 246 (83.4) 49 (16.6)
PIK3CA
Negative 129 (79.1) 34 (20.9)
Positive 471 (83.1) 96 (16.9) 1.334 0.247
CTEN
Negative 31 (79.5) 8 (20.5) 0.363 0.514
Positive 575 (83.2) 116 (16.8)
Abbreviations: CTEN¼C-terminal tensin-like; ER¼oestrogen receptor; HER2¼ human
epidermal growth factor receptor 2; PR¼progesterone receptors; TGF-b1= Transforming
Growth Factor b1.
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The associations of both nuclear and cytoplasmic ARGAP18
with the cadherin switch in the current data; E-cadherin loss and
N-cadherin gain, as well as the negative association with the EMT
triggers TGFb1 and PIK3CA (Zhao et al, 2006), as well as the
migration-associated CTEN (Albasri et al, 2009), reflects its
potential role in controlling cellular cytoskeletal dynamics and
migration. The latter is attributed to the recognised roles of Rho
GTPases in controlling the actin cytoskeleton. ARHGAP18 has
been postulated to suppress the function of RhoA and cause a
disruption in the production of stress fibres; contractile bundles of
actin found in non-muscle cells (Maeda et al, 2011). These
functions may suggest a mechanism through which ARHGAP18 is
involved in limiting spread and metastasis of cancer cells therefore
may provide some explanation for its good prognostic value.
High ARHGAP18 mRNA expression within the METABRIC data
set was significantly associated with variables of good prognosis
including the PAM50 and Integrative Clusters of good prognostic
classes. Although analysis of the METABRIC study revealed a trend
towards improved patients’ outcome in cases overexpressing
ARHGAP18, pooled analysis of the publicly available data sets, using
the bc-GenExMiner v4, showed significant association between
ARHGAP18 expression and better outcome. Although gene expres-
sion data reflect the overall expression levels, they show concordance
with our protein expression data where increased ARHGAP18
expression in both the nucleus and cytoplasm was significantly
associated with better outcome.
Table 4. Associations of nuclear H scores for ARHGAP18 in
relation to the clinicopathological parameters
ARHGAP18 Nuclear
Expression
Parameter
Low
expression
no. (%)
High
expression
no. (%) v2 P-value
Patients’ age
p50 yrs 320 (87.2) 47 (12.8) 0.585 0.471
450 yrs 525 (88.8) 66 (11.2)
Menopausal status
Premenopausal 335 (87.9) 46 (12.1) 0.047 0.838
Postmenopausal 510 (88.4) 67 (11.6)
Grade
1 103 (79.8) 26 (20.2)
12.832 0.0022 262 (87.3) 38 (12.7)
3 474 (91.0) 47 (9.0)
Mitotic figures
1 222 (82.8) 46 (17.2)
11.914 0.0032 176 (89.8) 20 (10.2)
3 422 (91.1) 41 (8.9)
Pleomorphisms
1 10 (76.9) 3 (23.1)
7.705 0.0212 267 (85.0) 47 (15.0)
3 542 (90.5) 57 (9.5)
Tubule formation
1 40 (88.9) 5 (11.1)
3.441 0.1792 264 (85.7) 44 (14.3)
3 516 (89.9) 58 (10.1)
Axillary nodal stage
1 496 (86.9) 75 (13.1)
2.656 0.2652 275 (90.5) 29 (9.5)
3 70 (89.7) 8 (10.3)
Tumour size
p2 cm 464 (85.5) 79 (14.5) 9.835 0.002
42 cm 372 (92.1) 32 (7.9)
NPI
Good (o3.4) 203 (82.2) 44 (17.8)
13.748 0.001Moderate (3.41–5.4) 475 (89.6) 55 (10.4)
Poor (X5.4) 162 (93.1) 12 (6.9)
Vascular invasion
Negative 531 (86.8) 81 (13.2) 3.372 0.066
Definite 297 (90.8) 30 (9.2)
Tumour type
Ductal carcinoma No
Special Type (NST)
529 (91.5) 49 (8.5)
Tubular mixed 136 (86.1) 22 (13.9)
Medullary (typical and
atypical)
20 (87.0) 3 (13.0) 21.170 0.002
Lobular* 59 (80.8) 14 (19.2)
Excellent Prognosis
Special Type**
29 (76.3) 9 (23.7)
Mixed NST and lobular 32 (82.1) 7 (17.9)
Mixed NST and other
special type
14 (73.7) 5 (26.3)
Abbreviation: NPI¼Nottingham Prognostic Index.
*Invasive lobular includes: classic lobular, tubulo-lobular, alveolar lobular, solid lobular,
pleomorphic lobular, and lobular mixed carcinomas.
**Excellent prognostic special types comprise: mucinous carcinoma, cribriform carcinoma,
tubular carcinoma and invasive papillary carcinoma.
Table 5. Association of nuclear ARHGAP18 expression and
the expression of other biomarkers
ARHGAP18 nuclear
expression Significance
Parameter
Low
expression
no. (%)
High
expression
no. (%) v2 P-value
ER
Negative 248 (91.5) 23 (8.5) 3.702 0.054
Positive 593 (87.1) 88 (12.9)
PR
Negative 369 (90.7) 38 (9.3) 3.381 0.066
Positive 453 (86.8) 69 (13.2)
HER2
Negative 683 (86.9) 103 (13.1) 11.433 0.003
Positive 127 (96.9) 4 (3.1)
Molecular subtypes
Luminal 528 (86.0) 86 (14.0)
13.522 0.001HER2þ 127 (96.9) 4 (3.1)
Triple negative 169 (90.4) 18 (9.6)
p53
Negative 567 (88.3) 75 (11.7) 0.032 0.859
Positive 244 (88.7) 31 (11.3)
Ki67
Low 179 (82.1) 39 (17.9) 10.599 0.001
High 481 (90.6) 50 (9.4)
E-cadherin
Negative 299 (90.6) 31 (9.4) 1.784 0.182
Positive 491 (87.7) 69 (12.3)
N-cadherin
Negative 156 (83.4) 31 (16.6) 10.828 0.002
Positive 470 (92.0) 41 (8.0)
TGF-b1
Negative 296 (86.0) 48 (14.0) 6.870 0.011
Positive 273(92.5) 22 (7.5)
PIK3CA
Negative 126 (77.3) 37 (22.7) 24.932 o 0.001
Positive 519 (91.5) 48 (8.5)
CTEN
Negative 29 (74.4) 10 (25.6) 8.836 0.007
Positive 620 (89.7) 71 (10.3)
Abbreviations: ER¼oestrogen receptor; HER2¼ human epidermal growth factor receptor
2; PR¼progesterone receptors.
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In conclusion, results presented herein suggest ARHGAP18 may be
acting, directly or indirectly, as a putative metastasis suppressor gene,
based on its association with favourable prognostic features including
negative association with LVI and longer survival at both protein and
mRNA expression levels. The general tumour suppressor effect
probably indicates that the relationship to LVI is perhaps within a
coordinated set of events related to multiple events in BC development
and progression. They also indicate the validity of our approach to
identify novel biomarkers associated with complex biological processes
that are related not only to the investigative techniques but also on
robust histological characterisation. Further investigation of this
biomarker as well as other genes differentially expressed with regard
to LVI is warranted to decipher the mechanism underlying its
development and to identify potential therapeutic targets.
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